Research article · 1 Jan 2026
Conference abstractPublished 5 Jan 2018
Extremely high levels of CA 19-9 levels detected in newly diagnosed patient with pancreatic adenocarcinoma
Rush University Medical Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pancreatic cancer has one of the highest mortality rates of any cancer with a poor prognosis and a five-year survival rate of 6%. CA 19-9 is the most well studied pancreatic cancer marker and is an important tool for diagnosis, prognosis and monitoring disease activity. We report a case study of a patient diagnosed with metastatic pancreatic cancer with exceedingly high levels of CA 19-9 not previously seen, to the best of our knowledge. A 72-year-old Hispanic male with a past medical history of colonic tubular adenoma and H. pylori, was referred to the gastroenterology clinic for rapid weight loss over two months, loss of appetite and abdominal pain. The laboratory work-up was significant for elevated liver enzymes, ALP 601, CA 19-9 281431, CEA 6.2. A CT scan showed numerous hypodense hepatic lesions, a hypodense pancreatic mass, and scattered sclerotic lesion of the right pelvis. A liver biopsy revealed adenocarcinoma consistent with pancreatobiliary primary, positive for cytokeratin 7. Given the metastatic picture, chemotherapy was suggested, however the patient elected to transfer to a different institution. CA 19-9 is produced by human pancreatic and biliary ductular cells. There is growing evidence demonstrating that high levels of CA 19-9 are associated with the severity of pancreatic malignancy. The high levels detected in our patient indicated advanced disease and poor prognosis. However, no reported cases of CA 19-9 levels greater than 200,000 have been reported in patients with pancreatic cancer and the precise mechanism of enormous elevation of CA 19-9 remains unclear
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Gastrointestinal & Digestive System.
Case report · 11 Nov 2025
Bitter Guard: A Gut Wrenching Surprise
Research article · 18 Jun 2025
Ursodeoxycholic Acid Treatment of LPAC Presenting as Post Cholecystectomy Pain: Rationale and Design of a Randomised Trial
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Gastrointestinal & Digestive System
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “F Khemani”
- BylineArticles whose byline prints “S Eswaran”